(Novo Nordisk’s competing GLP-1 medications ... post on her behalf. Jake Lahut WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of ...

But the booming business of off-brand versions of the blockbuster drugs, which trigger the hormone GLP-1 and curb hunger, has left many consumers wondering whether it is worth trying. Here’s ...

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy ... wrote in an email to The Washington Post. This article is part of The Post’s “Big Number” series ...

The future of the weight loss market might not revolve around GLP-1 drugs. By now ... the most promising alternatives might deliver some ideas for an investment. Let's dive in.

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to ... This story was updated to quote from a post from the founder and CEO of Hims & Hers ...

In the final weeks of his administration, President Biden’s Food and Drug Administration quietly ended the “shortage” of tirzepatide, a popular GLP-1 medication. That means on March 19 ...

His team is currently trying to determine whether GLP-1 drugs are associated with altered risks of post-surgical complications in patients without diabetes, as semaglutide and tirzepatide are also ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet ... without talking about GLP-1 medicines, so in true form ...

Oct 27 (Reuters) - The European Medicines Agency (EMA) on Friday said its safety panel did not find a causal link between popular GLP-1 drugs such ... clinical and post-marketing data of the ...